Volpara Health Receives FDA Clearance for Next-Generation Breast Density Algorithm and Architecture
SEATTLE, July 29, 2021 /PRNewswire/ --Volpara Health,aglobal health technology software leader providing an integrated breast care platform for the delivery of personalizedbreast care, has received FDA clearance for the latest version of its key science algorithm, Volpara Imaging Software (VIS 3.2).
- SEATTLE, July 29, 2021 /PRNewswire/ --Volpara Health,aglobal health technology software leader providing an integrated breast care platform for the delivery of personalizedbreast care, has received FDA clearance for the latest version of its key science algorithm, Volpara Imaging Software (VIS 3.2).
- VIS 3.2 improves the overall robustness of Volpara's industry-leading breast density assessment algorithm, incorporating learnings from artificial intelligence (AI).
- Since receiving initial FDA clearance for Volpara Imaging Software in 2010, Volpara has now received four additional clearances for the key science algorithm behind its integrated Volpara Breast Health Platforma product suite designed to enable earlier detection of breast cancers through improved mammography quality and workflow, volumetric assessment of breast density, and personalized breast care.
- The Volpara Breast Health Platform is supported by numerous patents, trademarks, and regulatory registrations, including FDA clearance and CE marking, and is validated by a volume of peer-reviewed publications unrivaled in the breast health industry.